Protocol for Cancloz: multicentre randomised, placebo-controlled, double-blind, parallel-group adaptive trial of cannabidiol for clozapine-resistant schizophrenia

Autor: Dan Siskind, Claudia Bull, Shuichi Suetani, Nicola Warren, Anastasia Suraev, Iain McGregor, Steve Kisely, Veronica De Monte, Mike Trott, Manju Shine, Vikas Moudgil, Gail Robinson, Stephen Parker, Ravikumar Krishnaiah, Terry Stedman, Allan Drummond, Sarah Medland, Ravi Iyer, Andrea Baker

Publikováno v: BJPsych Open, Vol 10 (2024)

Background Although clozapine is the most effective antipsychotic for people with treatment-resistant schizophrenia (TRS), only 40% of people with TRS respond, and there is limited evidence for augmentation agents. Cannabidiol (CBD) reduces positive

Externí odkaz: https://doaj.org/article/64ebe2dac8b946738e5425288d414a3a

CoMET: a randomised controlled trial of co-commencement of metformin versus placebo as an adjunctive treatment to attenuate weight gain in patients with schizophrenia newly commenced on clozapine

Autor: Dan Siskind, Anthony W. Russell, Shuichi Suetani, Dylan Flaws, Steve Kisely, Vikas Moudgil, Korinne Northwood, Gail Robinson, James G. Scott, Terry Stedman, Nicola Warren, Karl Winckel, Peter Cosgrove, Andrea Baker

Publikováno v: Therapeutic Advances in Psychopharmacology, Vol 11 (2021)

Background: There is limited evidence on interventions to minimise weight gain at clozapine commencement. We compared the effect of adjunctive metformin versus placebo at clozapine initiation. Methods: People with schizophrenia commencing on clozapin

Externí odkaz: https://doaj.org/article/0d237413545c4935ae8f88f52b0b3425

Electroconvulsive therapy, personal protective equipment and aerosol generating procedures: a review to guide practice during Coronavirus Disease 2019 (COVID-19) pandemic

Autor: Brett Emmerson, Jonathan Reinders, Simone Garrett-Walcott, Margaret Buda, Subramanian Purushothaman, Vikas Moudgil, David Fung

Publikováno v: Australasian Psychiatry. 28:632-635

Objective: To review the literature on the definition of aerosol-generating procedures (AGPs), identify high-risk AGPs, guidelines to use personal protective equipment (PPE) and review evidence to see if electroconvulsive therapy (ECT) is a high-risk

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ff93ac9f58ca3e2cb44c73c018e6a0c
https://doi.org/10.1177/1039856220953699

CoMET: a randomised controlled trial of co-commencement of metformin versus placebo as an adjunctive treatment to attenuate weight gain in patients with schizophrenia newly commenced on clozapine

Autor: James Scott, Karl Winckel, Andrea Baker, Peter Cosgrove, Anthony W. Russell, Gail Robinson, Korinne Northwood, Shuichi Suetani, Steve Kisely, Vikas Moudgil, Terry Stedman, Dylan Flaws, Dan Siskind, Nicola Warren

Publikováno v: Therapeutic Advances in Psychopharmacology, Vol 11 (2021)
Therapeutic Advances in Psychopharmacology

Background: There is limited evidence on interventions to minimise weight gain at clozapine commencement. We compared the effect of adjunctive metformin versus placebo at clozapine initiation. Methods: People with schizophrenia commencing on clozapin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edd0cd13431bf8e7e775bb95a4846468
https://doaj.org/article/0d237413545c4935ae8f88f52b0b3425

CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine

Autor: Savio Sardinha, Vikas Moudgil, Karl Winckel, Sue Patterson, Terry Stedman, Dan Siskind, Shuichi Suetani, Carmen C.W. Lim, Dylan Flaws, John J. McGrath, Andrea Baker, Anthony W. Russell, Nadia Friend, Steve Kisely

Publikováno v: BMJ Open
Siskind, D, Friend, N, Russell, A, McGrath, J J, Lim, C, Patterson, S, Flaws, D, Stedman, T, Moudgil, V, Sardinha, S, Suetani, S, Kisely, S, Winckel, K & Baker, A 2018, ' CoMET : A protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine ', BMJ Open, vol. 8, no. 3, e021000 . https://doi.org/10.1136/bmjopen-2017-021000

IntroductionClozapine, while effective in treatment refractory schizophrenia, is associated with significant weight gain, heart disease and increased risk of type 2 diabetes mellitus (T2DM). Although there is evidence for weight loss with metformin f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80ed33e61daf7e5b7c96251780a464a8
https://pubmed.ncbi.nlm.nih.gov/29500217